Cardiovascular effects of ghrelin antagonist in conscious rats

Regulatory Peptides

Volumn 156, Issue 1-3, 2009, Pages 72-76

  Vlasova, Maria A ^a   Järvinen, Kristiina ^a   Herzig, Karl Heinz ^b,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Antagonist; Blood pressure; Ghrelin; Heart rate; Hypertension; Radiotelemetry; Sympathetic nervous system

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIOBESITY AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; GHRELIN ANTAGONIST; PHENTOLAMINE; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR EFFECT; CONSCIOUSNESS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; HEART RATE; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; TACHYCARDIA; TELEMETRY;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ATENOLOL; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CONSCIOUSNESS; GHRELIN; HEART RATE; MALE; OLIGOPEPTIDES; PHENTOLAMINE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ADRENERGIC, BETA-1; SYMPATHETIC NERVOUS SYSTEM;

ANIMALIA; MUS; RATTUS;

EID: 67449110701     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.04.016     Document Type: Article

References (34)

1. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
2. Tschöp M., Smiley D.L., and Heiman M.L. Ghrelin induces adiposity in rodents. Nature 407 (2000) 908-913
3. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., and Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 409 (2001) 194-198
4. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., Hamelin M., Hreniuk D.L., Palyha O.C., Anderson J., Paress P.S., Diaz C., Chou M., Liu K.K., McKee K.K., Pong S.S., Chaung L.Y., Elbrecht A., Dashkevicz M., Heavens R., Rigby M., Sirinathsinghji D.J., Dean D.C., Melillo D.G., Patchett A.A., Nargund R., Griffin P.R., DeMartino J.A., Gupta S.K., Schaeffer J.M., Smith R.G., and Van der Ploeg L.H. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273 (1996) 974-977
5. Banks W.A., Tschöp M., Robinson S.M., and Heiman M.L. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 302 (2002) 822-827
6. Smith R.G., Feighner S., Prendergast K., Guan X., and Howard A. A new orphan receptor involved in pulsatile growth hormone release. Trends Endocrinol Metab 10 (1999) 128-135
7. Gnanapavan S., Kola B., Bustin S.A., Morris D.G., McGee P., Fairclough P., Bhattacharya S., Carpenter R., Grossman A.B., and Korbonits M. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87 (2002) 2988-2991
8. Bodart V., Bouchard J.F., McNicoll N., Escher E., Carrière P., Ghigo E., Sejlitz T., Sirois M.G., Lamontagne D., and Ong H. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res 85 (1999) 796-802
9. Muccioli G., Broglio F., Valetto M.R., Ghè C., Catapano F., Graziani A., Papotti M., Bisi G., Deghenghi R., and Ghigo E. Growth hormone-releasing peptides and the cardiovascular system. Ann Endocrinol (Paris) 61 (2000) 27-31
10. Papotti M., Ghè C., Cassoni P., Catapano F., Deghenghi R., Ghigo E., and Muccioli G. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 85 (2000) 3803-3807
11. Nagaya N., Uematsu M., Kojima M., Ikeda Y., Yoshihara F., Shimizu W., Hosoda H., Hirota Y., Ishida H., Mori H., and Kangawa K. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104 (2001) 1430-1435
12. Okumura H., Nagaya N., Enomoto M., Nakagawa E., Oya H., and Kangawa K. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 39 (2002) 779-783
13. Matsumura K., Tsuchihashi T., Fujii K., Abe I., and Iida M. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 40 (2002) 694-699
14. Lin Y., Matsumura K., Fukuhara M., Kagiyama S., Fujii K., and Iida M. Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. Hypertension 43 (2004) 977-982
15. Xu X.B., Pang J.J., Cao J.M., Ni C., Xu R.K., Peng X.Z., Yu X.X., Guo S., Chen M.C., and Chen C. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. Am J Physiol Heart Circ Physiol 289 (2005) 1643-1651
16. García E.A., and Korbonits M. Ghrelin and cardiovascular health. Curr Opin Pharmacol 6 (2006) 142-147
17. Asakawa A., Inui A., Kaga T., Katsuura G., Fujimiya M., Fujino M.A., and Kasuga M. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52 (2003) 947-952
18. Horvath T.L., Castañeda T., Tang-Christensen M., Pagotto U., and Tschöp M.H. Ghrelin as a potential anti-obesity target. Curr Pharm Des 9 (2003) 383-395
19. Zhao H., and Liu G. Growth hormone secretagogue receptor antagonists as anti-obesity therapies? Still an open question. Curr Opin Drug Discov Dev 9 (2006) 509-515
20. Matsukawa K., and Ninomiya I. Anesthetic effects on tonic and reflex renal sympathetic nerve activity in awake cats. Am J Physiol 256 (1989) 371-378
21. Broccardo M., and Improta G. Sauvagine-induced hypothermia: evidence for an interaction with the dopaminergic system. Eur J Pharmacol 258 (1994 13) 179-184
22. Keeton T.K., and Biediger A.M. Propranolol and atenolol inhibit norepinephrine spillover rate into plasma in conscious spontaneously hypertensive rats. Naunyn-Schmiedeberg's Arch Pharmacol 344 (1991) 47-55
23. de Menezes R.C., Zaretsky D.V., Sarkar S., Fontes M.A., and Dimicco J.A. Microinjection of muscimol into the periaqueductal gray suppresses cardiovascular and neuroendocrine response to air jet stress in conscious rats. Am J Physiol Regul Integr Comp Physiol 295 (2008) 881-890
24. Shinde U.A., Desai K.M., Yu C., and Gopalakrishnan V. Nitric oxide synthase inhibition exaggerates the hypotensive response to ghrelin: role of calcium-activated potassium channels. J Hypertens 23 (2005) 779-784
25. Soares J.B., Rocha-Sousa A., Castro-Chaves P., Henriques-Coelho T., and Leite-Moreira A.F. Inotropic and lusitropic effects of ghrelin and their modulation by the endocardial endothelium, NO, prostaglandins, GHS-R1a and KCa channels. Peptides 27 (2006) 1616-1623
26. Rossi F., Castelli A., Bianco M.J., Bertone C., Brama M., and Santiemma V. Ghrelin inhibits contraction and proliferation of human aortic smooth muscle cells by cAMP/PKA pathway activation. Atherosclerosis 203 (2009) 97-104
27. Soeki T., Kishimoto I., Schwenke D.O., Tokudome T., Horio T., Yoshida M., Hosoda H., and Kangawa K. Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol 294 (2008) 426-432
28. Kamimura K., Nishimura H., and Bailey J.R. Blockade of beta-adrenoceptor in control of blood pressure in fowl. Am J Physiol 269 (1995) 914-922
29. Shimizu Y., Nagaya N., Teranishi Y., Imazu M., Yamamoto H., Shokawa T., Kangawa K., Kohno N., and Yoshizumi M. Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochem Biophys Res Commun 310 (2003) 830-835
30. Iantorno M., Chen H., Kim J.A., Tesauro M., Lauro D., Cardillo C., and Quon M.J. Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab 292 (2007) 756-764
31. Xu X., Jhun B.S., Ha C.H., and Jin Z.G. Molecular mechanisms of ghrelin-mediated endothelial nitric oxide synthase activation. Endocrinology 149 (2008) 4183-4192
32. Wren A.M., Small C.J., Abbott C.R., Dhillo W.S., Seal L.J., Cohen M.A., Batterham R.L., Taheri S., Stanley S.A., Ghatei M.A., and Bloom S.R. Ghrelin causes hyperphagia and obesity in rats. Diabetes 50 (2001) 2540-2547
33. Asakawa A., Inui A., Kaga T., Yuzuriha H., Nagata T., Ueno N., Makino S., Fujimiya M., Niijima A., Fujino M.A., and Kasuga M. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120 (2001) 337-345
34. Rudolph J., Esler W.P., O'connor S., Coish P.D., Wickens P.L., Brands M., Bierer D.E., Bloomquist B.T., Bondar G., Chen L., Chuang C.Y., Claus T.H., Fathi Z., Fu W., Khire U.R., Kristie J.A., Liu X.G., Lowe D.B., McClure A.C., Michels M., Ortiz A.A., Ramsden P.D., Schoenleber R.W., Shelekhin T.E., Vakalopoulos A., Tang W., Wang L., Yi L., Gardell S.J., Livingston J.N., Sweet L.J., and Bullock W.H. Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity. J Med Chem 50 (2007) 5202-5216